Rivaroxaban attenuates neutrophil maturation in the bone marrow niche.

Authors:
Schneckmann R; Döring M; Gerfer S; Gorressen S; Heitmeier S and 7 more

Journal:
Basic Res Cardiol

Publication Year: 2023

DOI:
10.1007/s00395-023-01001-5

PMCID:
PMC10425524

PMID:
37580509

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Basic Res Cardiol

Abbreviation: Basic Res Cardiol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial ca…
Paasche A; Wiedmann F; Kraft M and 16 more (2024) - Transparency Score: 3/6
Macrophage-based therapeutic approaches for cardiovascular diseases.
Sansonetti M; Al Soodi B; Thum T and 1 more (2024) - Transparency Score: 3/6
Pinacidil ameliorates cardiac microvascular ischemia-reperfusion injury by inhibiting chaperone-med…
Liu M; Li S; Yin M and 13 more (2024) - Transparency Score: 3/6
Activation of the integrated stress response rewires cardiac metabolism in Barth syndrome.
Kutschka I; Bertero E; Wasmus C and 22 more (2023) - Transparency Score: 3/6
Electrophysiological and calcium-handling development during long-term culture of human-induced plu…
Seibertz F; Sutanto H; Dülk R and 19 more (2023) - Transparency Score: 5/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflicts of interestNo conflicts of interest are reported by the authors. Conflicts of interest No conflicts of interest are reported by the authors."

Evidence found in paper:

"Funding Open Access funding enabled and organized by Projekt DEAL. This work was supported by funding of the Deutsche Forschungsgemeinschaft SFB 1116 (B10 to MG and UF, B06 to CJ, B11 to AP, B12 to MK), TRR259 (B03 to UF and B10 to MG), and IRTG 1902 (P12 to MG). We thank Bayer AG for providing rivaroxaban and Stefan Heitmeier for intensive discussions. The funders had no influence on the study design or data collection."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025